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Abstract In healthy human myocardium a tight balance
exists between receptor-mediated kinases and phosphatases
coordinating phosphorylation of regulatory proteins involved
in cardiomyocyte contractility. During heart failure, when
neurohumoral stimulation increases to compensate for
reduced cardiac pump function, this balance is perturbed. The
imbalance between kinases and phosphatases upon chronic
neurohumoral stimulation is detrimental and initiates cardiac
remodelling, and phosphorylation changes of regulatory
proteins, which impair cardiomyocyte function. The main
signalling pathway involved in enhanced cardiomyocyte
contractility during increased cardiac load is the b-adrenergic
signalling route, which becomes desensitized upon chronic
stimulation. At the myofilament level, activation of protein
kinase A (PKA), the down-stream kinase of the b-adrenergic
receptors (b-AR), phosphorylates troponin I, myosin binding
protein C and titin, which all exert differential effects on
myofilament function. As a consequence of b-AR down-
regulation and desensitization, phosphorylation of the PKA-
target proteins within the cardiomyocyte may be decreased
and alter myofilament function. Here we discuss involvement
of altered PKA-mediated myofilament protein phosphoryla-
tion in different animal and human studies, and discuss the
roles of troponin I, myosin binding protein C and titin in
regulating myofilament dysfunction in cardiac disease. Data
from the different animal and human studies emphasize the
importance of careful biopsy procurement, and the need to
investigate localization of kinases and phosphatases within the
cardiomyocyte, in particular their co-localization with cardiac
myofilaments upon receptor stimulation.
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Introduction
In healthy humans, the sympathetic nervous system (SNS)
as well as the renin-angiotensin-aldosterone system are
important mechanisms to maintain adequate perfusion of
vital organs via peripheral vasoconstriction, an increase in
heart rate and an improvement of myocardial contractility.
Although aimed at maintaining cardiac pump function,
chronic neurohumoral stimulation in patients with
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cardiovascular disease is detrimental for cardiac function
(Packer 1995) illustrated by the negative correlation
between noradrenaline plasma levels and prognosis of the
patient (Cohn et al. 1984) and by the improvement of
symptoms and prolonged survival of patients treated with
neurohumoral antagonists (Bohm and Maack 2000).
Activation of the b-adrenergic receptors by SNS is the
main signalling route responsible for increasing cardio-
myocyte contractility. Beta-adrenergic receptor (b-AR)
stimulation induces protein kinase A (PKA)-mediated
phosphorylation of L-type Ca2? channels and ryanodine
receptors, increasing cytosolic Ca2?, and of phospholam-
ban, increasing activity of the SR Ca2?-ATPase pump and
SR Ca2? uptake and loading (Bers 2002). At the myofila-
ment level, PKA-mediated phosphorylation of troponin I
(cTnI) and myosin binding protein C (cMyBP-C) decrease
myofilament Ca2?-sensitivity (Wolff et al. 1996; Cazorla
et al. 2006) and contribute to an acceleration of cardiac
relaxation (Solaro et al. 1976; Zhang et al. 1995; Kentish
et al. 2001). Stelzer et al. (2007) have proposed a dominant
role for cMyBP-C phosphorylation in regulating the rate of
cross-bridge cycling and force development upon b-AR
stimulation. Moreover, several studies revealed a role for
PKA-mediated phosphorylation of titin in regulating car-
diomyocyte stiffness (Fukuda et al. 2005; Borbe´ly et al.
2005; Kru¨ger and Linke 2006).
Chronic SNS activation in cardiovascular disease results
in down-regulation and uncoupling of b-adrenergic recep-
tors (Harding et al. 1994; Bristow 2000) and thereby limits
cardiac responsiveness during increased cardiac load as
occurs during exercise. In human heart failure, down-reg-
ulation and uncoupling of the b-AR pathway leads to
decreased PKA-mediated phosphorylation of Ca2? han-
dling and myofilament proteins. Here we present data from
different animal (mouse, rat, pig) and human heart failure
models in support for reduced b-AR-mediated signalling
and defects in myofilament function.
Materials and methods
Cardiac tissue
All animal experiments were performed in accordance with
the guide for the care and use of laboratory ANIMALS
(NIH Publication 86–23, revised 1996), and with approval
of the Animal Care Committee of the VU Medical Center
and of the Erasmus Medical Center. Cardiac samples from
the left (LV) or right (RV) ventricular wall were obtained
from control and diseased: mouse (myocardial infarction,
MI), rat (pressure overload), pig (MI) and human (ischemic
heart disease, ISHD; idiopathic dilated cardiomyopathy,
IDCM) myocardium.
Mice
In mice (C57B1/6 J of either sex) myocardial infarction
(n = 7) was produced by permanent ligation of the left
anterior descending coronary artery as described before (de
Waard et al. 2007). Sham animals (n = 6) underwent the
operation without infarct induction. Cardiomyocyte mea-
surements and protein analysis were performed in tissue
from remodelled LV myocardium.
Rats
Animals (male, Wistar; body weight 175 g) received a
single subcutaneous injection of 80 mg kg-1 monocrota-
line (n = 10) (Lamberts et al. 2007). During its first
passage through the pulmonary circulation monocrotaline
damages the pulmonary endothelium, thereby inducing
pulmonary hypertension, causing right ventricular (RV)
hypertrophy resulting eventually in RV heart failure (Lei-
neweber et al. 2000; Korstjens et al. 2002). Sham animals
(control, n = 11) received a saline injection. Cardiomyo-
cyte measurements and protein analysis were preformed in
isolated skinned cardiomyocytes obtained from RV tissue
of quiescent control and failing hearts.
Pigs
In pigs (2–3 month old Yorkshire-Landrace pigs of either
sex) the left circumflex coronary artery was permanently
ligated to produce a myocardial infarction (n = 6) (van
Kats et al. 2000; van der Velden et al. 2004). In sham
animals (n = 7) the suture was removed. Three weeks
after surgery (transmural, 0.5 mg wet weight) needle
biopsies were taken from the LV anterior free wall myo-
cardium (in MI pigs: remodelled non-infarcted tissue) and
immediately frozen and stored in liquid nitrogen (Zaremba
et al. 2007). Cardiomyocyte measurements and protein
analysis were performed in the subendocardial part of the
biopsies.
Human
Within the human studies LV tissue samples were obtained
during heart transplantation surgery from patients with
end-stage ischemic (n = 10) and dilated cardiomyopathy
(n = 5) (NYHA class IV) (Messer et al. 2007; Hamdani
et al. 2008). Non-failing heart tissue was obtained from
donor hearts (n = 10) when no suitable transplant recipient
was found. The donors had no history of cardiac disease, a
normal cardiac examination, normal ECG and normal
ventricular function on echocardiography within 24 h of
heart explantation. The tissue was collected in cardioplegic
solution and stored in liquid nitrogen. Samples were
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obtained after informed consent and with approval of the
local Ethical Committee (St. Vincents’ Hospital Human
Research Ethics Committee: file number: H03/118; Title:
Molecular Analysis of Human heart Failure).
Cardiomyocyte measurements
Single cardiomyocytes were obtained via mechanical iso-
lation from left or right ventricular tissue samples, and
incubated for 5 min with Triton X-100 (0.5%) to remove
all membranes. Isometric force was measured at various
calcium concentrations (pCa, -log[Ca2?], ranged from 4.5
to 9) at 15C and sarcomere length of 2.2 lm. Figure 1a
shows a single human cardiomyocyte glued between a
force transducer and a motor. After maximal activation 4–5
measurements were carried out at submaximal [Ca2?]
followed by a maximal activation. Force values obtained in
solutions with submaximal [Ca2?] were normalized to the
interpolated maximal force values. In a number of cells
force measurements were repeated after incubation with
the catalytic subunit of protein kinase A (PKA, 40 min;
20C; 100 U/ml, Sigma). Force registrations before and
after PKA at maximal [Ca2?] (pCa 4.5) and submaximal
[Ca2?] (pCa 5.6) are shown in Fig. 1b. Maximal calcium
activated tension (Fmax, i.e., maximal force/cross-sec-
tional area) was calculated by subtracting passive force
(Fpas) from the total force (Ftotal) at saturating [Ca2?]
(pCa 4.5) (Fig. 1b). Passive tension (Fpas) was determined
by shortening the cell in relaxation solution (pCa 9.0) by
20%. Ca2?-sensitivity is denoted as pCa50, i.e., pCa value
at which 50% of Fmax is reached.
In vitro motility assay
Thin filament Ca2? regulatory function of human troponin
was studied with the quantitative in vitro motility assay.
Regulation of TRITC-Phalloidin labelled actin (actin-U)
filaments movement over immobilised rabbit fast muscle
heavy meromyosin (Fraser and Marston 1995; Messer et al.
2007) was defined as fraction of filaments motile and
filament sliding speed. The actomyosin was reconstituted
in a flow cell, constructed from a microscope slide and a
siliconised coverslip. Actin-U was premixed with tropo-
myosin and troponin at a 109 working concentration prior
to dilution and infusion into the assay flow cell. Thin
filament movement over a bed of immobilised rabbit fast
muscle heavy meromyosin (100 lg/ml) was performed and
analysed as before (Knott et al. 2002). Affinity chroma-
tography on immobilised monoclonal anti-troponin I
antibody was used for purification of the whole troponin
complex from human failing (IDCM) and non-failing donor
myocardium as described previously (Messer et al. 2007).
 20 µm 
A
B pCa 5.6 pCa 4.5 
Fig. 1 Force measurements in
single permeabilized
cardiomyocytes. a Single
human cardiomyocyte at a
sarcomere length of 2.2 lm.
b Isometric force measured at
maximal [Ca2?] (pCa 4.5) and
submaximal [Ca2?] (pCa 5.6)
before and after protein kinase
A in a cardiomyocyte from a
patient with heart failure
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Phosphorylation status of myofilament proteins
ProQ phosphostaining
Cardiac tissue samples (*0.5–5.0 mg dry weight) were
TCA (tri-chloro acetic acid)-treated as described previ-
ously (Zaremba et al. 2007). Phosphorylation status of b-
AR target proteins, myosin binding protein C (cMyBP-C)
and troponin I (cTnI), and other myofilament proteins
[desmin, troponin T (cTnT) and myosin light chain 2
(MLC2)] was determined using Pro-Q Diamond phospho-
staining (Molecular Probes). Samples were separated on a
gradient gel (Criterion Tris–HCl 4–15% gel, BioRad) and
proteins were stained for 1 h with Pro-Q diamond phos-
phoprotein stain. Fixation, washing and de-staining were
performed according to the manufacturers guidelines.
Staining was visualized using the LAS-3000 Image Reader
(FUJI; 460/605 nm Ex/Em; 2 min illumination) and signals
were analyzed with AIDA. All protein signals were within
the linear range. Subsequently gels were stained overnight
with SYPRO Ruby stain (Molecular Probes) and visualized
with the LAS-3000 (460/605 nm Ex/Em; 2 s illumination).
The phosphorylation signals of myofilament proteins were
normalized to SYPRO-stained cMyBP-C to correct for
minor differences in protein loading.
Western immunoblotting
Gel electrophoresis (15% acrylamide gels) and Western
immunoblotting was performed to analyze bisphosphory-
lation of cTnI at Ser-23/24 (i.e., PKA-sites, rabbit
polyclonal Ab, dilution 1:500, Cell signalling). All signals
were normalized to Ponceau-stained actin to correct for
differences in protein loading.
Statistical analysis
Data are given as means ± SEM. Data of control and
failing animals/human were compared using unpaired
Student t-tests. Effects of PKA were tested by paired stu-
dent t-tests. The differences in pCa50 between groups were
tested with one-way analysis of variance (ANOVA). Sig-
nificance was accepted when P \ 0.05. All protein signals
were visualized using the LAS-3000 image reader (FUJI)
and signals were analyzed with AIDA software (Raytest).
Results
Enhanced myofilament Ca2?-sensitivity in cardiac
disease
Force measurements in single cardiomyocytes revealed an
increase in myofilament Ca2?-sensitivity in diseased
(failing) myocardium in comparison to control/sham (non-
failing) hearts. Figure 2a illustrates a leftward shift of the
force-pCa relationship in all failing models. The difference
in pCa50 between failing and non-failing tissue differed
significantly among groups (1-way ANOVA, P \ 0.001)
and was smallest in the mouse myocardial infarction model
(DpCa50 = 0.05 ± 0.01), and amounted to 0.07 ± 0.01 in
rat, 0.12 ± 0.01 in pig and 0.14 ± 0.02 in human (Fig. 2c).
Correction of enhanced myofilament Ca2?-sensitivity
by exogenous protein kinase A
Cardiomyocyte force measurements were repeated after
incubation with exogenous protein kinase A. Consistent
with previous studies, PKA reduced Ca2?-sensitivity of the
myofilament in all samples (van der Velden et al. 2003;
E´des et al. 2008). This is illustrated by the reduction in
force development after PKA at submaximal [Ca2?] (pCa
5.4) in Fig. 1b. Incubation with PKA abolished the dif-
ference in baseline Ca2?-sensitivity in all groups (Fig. 3a).
The reduction in pCa50 was significantly larger in failing
compared to non-failing hearts in all models (Fig. 3b).
Among the failing groups the shift in pCa50 (DpCa50) was
smallest in MI mice and largest in end-stage failing human
cardiomyocytes.
Altered thin filament regulation
To study if changes in troponin phosphorylation account
for altered contractile function, Ca2?-regulation of recon-
stituted thin filaments was studied using quantitative in
vitro motility assay. Ca2?-regulation of actin motiltity by
troponin was studied comparing troponin from failing
(IDCM) and non-failing (donor) human myocardium. In
Fig. 4a thin filament sliding speed and motile fraction are
plotted as a function of [Ca2?] (i.e., pCa). Failing heart thin
filament Ca2?-sensitivity was always significantly higher
than non-failing for both sliding speed (DpCa50 = 0.39)
and fraction motile (DpCa50 = 0.38). Ca
2?-sensitivity of
thin filament regulation was decreased when non-failing
troponin was reconstituted with recombinant PKA-phos-
phorylated human cTnI (not shown; Messer et al. 2007).
When failing and non-failing donor troponin were recon-
stituted with recombinant human cTnI phosphorylated with
PKA, Ca2?-regulation of thin filaments was similar for
failing and non-failing troponin (Fig. 4b).
Reduction in maximal force generating capacity
in cardiac disease
While force generation at low calcium concentrations was
higher in cardiomyocytes from failing compared to non-
failing hearts, the maximal force generating capacity was
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significantly lower in the infarct mouse (sham:
18.5 ± 1.8 kN/m2 and MI: 14.6 ± 1.1 kN/m2) and pig
model. Figure 2b illustrates the absolute force values
plotted as function of pCa in the pig model, illustrating the
reduction in myofilament force development in cardio-
myocytes from post-infarct remodelled myocardium. PKA
did not abolish the difference in Fmax (not shown). Fmax
did not differ in the failing rat model (control:
24.4 ± 2.6 kN/m2 and failing: 29.0 ± 2.1 kN/m2) and
between human ISHD (33.1 ± 3.0 kN/m2) and donor
(33.8 ± 2.5 kN/m2) cardiomyocytes.
Correction of enhanced cardiomyocyte stiffness
by protein kinase A
Passive force did not significantly differ between cells from
failing and non-failing hearts in the mouse, rat and pig
model, while cardiomyocyte stiffness was significantly
lower in ISHD compared to non-failing donor (Fig. 5a).
PKA reduced Fpas in all models. Noteworthy, recent
studies in cardiomyocytes isolated from human biopsies
(Borbe´ly et al. 2005; van Heerebeek et al. 2006), which
were taken during cardiac catheterization revealed
enhanced cardiomyocyte stiffness in patients with heart
failure. The Fpas was significantly lowered upon incuba-
tion with PKA. Figure 5b shows Fpas in cardiomyocytes
from heart failure patients with reduced left ventricular
ejection fraction (HFREF; NYHA II-III) in comparison to
controls. In both HFREF and controls PKA significantly
reduced cardiomyocyte stiffness. The reduction in Fpas
upon PKA is also illustrated in Fig. 1b.
Phosphorylation status of myofilament proteins
ProQ Diamond staining of a pig sample incubated with and
without PKA showed increased phosphorylation of the b-
AR myofilament target proteins, cMyBP-C and cTnI, while
MLC2 phosphorylation was decreased during the incuba-
tion (Fig. 6a). ProQ Diamond stained samples from mouse,
rat, pig and human samples are shown in Fig. 6b.
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 PIGB C
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Fig. 2 Ca2?-sensitivity of
myofilaments in different
species. a Ca2?-sensitivity of
the myofilaments was
significantly higher in failing
compared to non-failing
controls in all studies. b A
reduction in maximal force
generating capacity was
observed in post-infarct
remodelled myocardium. c 
P \ 0.05, animal versus human
in Bonferroni post-test analysis
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Phosphorylation signals were normalized to the SYPRO-
stained cMyBP-C band in the same samples to correct for
small differences in protein loading. Moreover, to correct
for differences in staining between gels the Peppermint-
Stick Phosphoprotein marker (PPM, Molecular Probes)
was used as described previously (Zaremba et al. 2007; see
PPM in Fig. 7). This marker contains phosphorylated
ovalbumin. The ProQ Diamond signal for ovalbumin is
divided by the SYPRO-stained ovalbumin band, which is
subsequently used as correction factor for inter-gel
differences.
Analysis of the average values for myofilament protein
phosphorylation, obtained after correction for protein
loading and inter-gel differences, revealed reduced phos-
phorylation of cMyBP-C and cTnI in failing human
compared to non-failing donor myocardium (Fig. 6c). No
significant changes in myofilament protein phosphorylation
were observed between failing and non-failing mouse and
rat samples. In pig myocardium, MLC2 phosphorylation
was significantly lower in MI compared to sham. A similar
reduction in MLC2 phosphorylation was observed in fail-
ing rat hearts compared to shams, although the difference
was not significant (P = 0.08). In contrast, MLC2 phos-
phorylation was significantly higher in end-stage human
ISHD than in non-failing donor hearts.
Noteworthy, phosphorylation of cTnI was much higher
in mice cardiac samples in comparison to myocardium
from other species, in particular pig and human. To
determine if PKA is able to increase cTnI phosphorylation
in human myocardium to values observed in mice myo-
cardium, a donor and failing human sample were treated
with exogenous PKA. The gels shown in Fig. 7 illustrate
that the effect of PKA on protein phosphorylation was only
minor in the non-failing donor sample (5% increase in
cMyBP-C, no effect on cTnI), while PKA increased
cMyBP-C and cTnI phosphorylation in the failing sample
by 27 and 130%, respectively. These data show that PKA-
phosphorylation in non-failing donor myocardium is
almost saturated. The relatively high phosphorylation sta-
tus of cTnI observed in particular in mouse myocardium
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Fig. 3 Effect of protein kinase
A on myofilament Ca2?-
sensitivity. a Force-pCa
relations after incubation with
PKA. After PKA myofilament
Ca2?-sensitivity did not differ
between failing and non-failing
cardiomyocytes. b Change in
pCa50 (DpCa50) upon PKA in all
groups. *P \ 0.05, failing
versus non-failing in unpaired
student t-test
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Fig. 4 Ca2?-regulation of thin
filaments by human troponin.
Ca2?-regulation of thin filament
motility by non-failing and
failing heart troponin was
compared in dual chambered
motility cells. a Thin filament
Ca2?-sensitivity was higher for
failing than non-failing
troponin, both for sliding speed
and fraction motile. b The
difference was abolished when
failing and non-failing troponin
were reconstituted with PKA-
phosphorylated recombinant
human cTnI
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Fig. 5 Cardiomyocyte
stiffness. a Protein kinase A
(PKA) reduced cardiomyocyte
passive force (Fpas). b Force
measurements in
cardiomyocytes from human
cathether biopsies revealed
enhanced cardiomyocyte
stiffness in heart failure patients
with reduced left ventricular
ejection fraction (HFREF)
compared to controls.
*P \ 0.05, failing versus non-
failing in unpaired student t-test;
#P \ 0.05, effect PKA in paired
student t-test
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Fig. 6 ProQ-phosphostaining of myofilament proteins. a Pig samples
treated with and without PKA, stained with ProQ diamond. b ProQ
diamond staining of cardiac samples from mouse, rat, pig and human
cardiac samples. Mean values for protein phosphorylation (relative to
SYPRO-stained cMyBP-C) are given in c Abbreviations: MHC
myosin heavy chain; cMyBP-C myosin binding protein C; cTnT
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Fig. 7 SYPRO and ProQ-phospho staining of human cardiac samples
treated with PKA. PKA incubation of a donor sample slightly increased
cMyBP-C, but did not increase cTnI phosphorylation, while an
increased ProQ-staining of cMyBP-C and cTnI was observed in failing
myocardium treated with PKA. Please note that MLC2 phosphorylation
was preserved during PKA treatment as the specific PP1 inhibitor,
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sin heavy chain; cMyBP-C myosin binding protein C; cTnT troponin T;
cTnI troponin I; MLC2 myosin light chain 2
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might reflect phosphorylation at other sites, possibly tar-
geted by PKC, and may be related to differences between
species and/or tissue handling.
Western immunoblot analysis of cTnI phosphorylation
at serines 23/24 revealed significantly lower phosphoryla-
tion at the PKA-sites of cTnI in ISHD compared to non-
failing donor myocardium (Fig. 8a, b), while no significant
differences were observed in the animal models. It should
be noted that the antibody only detects the PKA-bis-
phosphorylated form of cTnI and not mono-phosphorylated
cTnI forms. As our analysis cannot distinguish between
mono-phosphorylation of PKA-sites, a difference in the
mono-phosphorylated forms of cTnI may still be present
between failing and non-failing myocardium.
Discussion
Activation of the b-AR pathway results in enhanced car-
diac contractile performance in response to increased
circulatory demand. However, reduced responsiveness to
b-AR stimulation in heart failure is thought to limit cardiac
performance during exercise. Functional data from all our
animal and human studies are in support of reduced b-AR
signalling, as baseline myofilament dysfunction (i.e.,
enhanced Ca2?-sensitivity and cardiomyocyte stiffness)
was restored upon incubation with exogenous protein
kinase A. However, analysis of the phosphorylation status
of b-AR target proteins revealed reduced PKA-mediated
phosphorylation only in end-stage failing human myocar-
dium. Moreover, the reduction in maximal force generating
capacity was only observed in post-infarct remodelled
myocardium early after MI (mouse and pig model), and
could not be restored by PKA. The discrepancies in
myofilament function and protein phosphorylation are
discussed below.
Enhanced myofilament Ca2?-sensitivity and stiffness
In healthy myocardium, myofilament Ca2?-sensitivity is
reduced upon b-AR stimulation and is thought to exert
a positive lusitropic effect on cardiac performance
(Kobayashi and Solaro 2005). The reduction in myofilament
Ca2?-sensitivity has been ascribed to PKA-mediated
phosphorylation of cTnI and cMyBP-C (Wolff et al. 1996;
Cazorla et al. 2006). As a consequence of reduced b-AR
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Fig. 8 PKA-mediated cTnI
phosphorylation. a Western
immunoblot analysis revealed
reduced PKA-mediated
phosphorylation at Ser 23/24 in
cTnI in ISHD compared to non-
failing human myocardium.
b Phosphorylation signals of
cTnI were normalized to
Ponceau-stained actin to correct
for differences in protein
loading. n number of heart
samples. *P \ 0.05, ISHD
versus donor in unpaired student
t-test
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signalling in heart failure, reduced PKA-mediated
phosphorylation would result in an enhanced myofilament
Ca2?-sensitivity. Our functional measurements in single
cardiomyocytes revealed an increase in myofilament
Ca2?-sensitivity in all failing heart models (Fig. 2a), which
could be corrected by exogenous PKA (Fig. 3). In vitro
motility analysis of regulation of thin filament movement by
troponin from failing and non-failing human myocardium
revealed a similar increase in Ca2?-sensitivity in failing
myocardium (Fig. 4a). Moreover, troponin regulation of thin
filaments was similar when failing and non-failing human
troponin was reconstituted with PKA-phosphorylated
recombinant human cTnI (Fig. 4b). This indicates
that reduced phosphorylation of the PKA-sites in cTnI
(Ser 23/24) accounts for the enhanced myofilament Ca2?-
sensivity observed in end-stage failing human myocardium.
The difference in Ca2?-sensitivity between failing and
non-failing hearts was smallest in mice and largest in
human. The relatively small difference between MI and
sham mice (Fig. 2a) and small effects of PKA (Fig. 3a)
may be explained by the relatively high baseline cTnI
phosphorylation status (Fig. 6) in these animals. Defects in
b-AR signalling may be difficult to uncover in mice due to
the small dynamic range in response to b-AR stimulation.
Although, the direction of the change in pCa50 was similar
in all heart failure models, Bonferroni post-test analysis
revealed that the difference in pCa50 (DpCa50) between
failing and non-failing cardiomyocytes was significantly
larger in human compared to the mouse and rat model,
while DpCa50 (failing versus non-failing) did not differ
from the pig model (Fig. 2c). Hence, large animal models
may be more representative to investigate consequences of
b-AR stimulation on myofilament protein phosphorylation
and function.
Alternatively, the smaller differences in pCa50 in rodents
and absence of reduced phosphorylation of b-AR target
proteins in animal models in contrast to human, may be a
reflection of disease progression, as the human studies
involve end-stage heart failure. During earlier stages of
heart failure, such as present in the animal studies, defects
in b-AR signalling may be less severe, and the functional
and proteomic phenotype observed in less severe stages of
cardiac disease may be the resultant of changes in other
signalling pathways as well. Within our human studies we
observed a striking difference in cardiomyocyte stiffness,
which may relate to severity of cardiac disease. In agree-
ment with previous studies (Makarenko et al. 2004;
Nagueh et al. 2004; Neagoe et al. 2002) cardiomyocyte
stiffness in end-stage human heart failure was lower in
comparison to non-failing donors (Fig. 5a). It has been
proposed that the reduction in Fpas is due to a shift in titin
isoform composition, from the stiff N2B to the more
compliant N2BA isoform (Makarenko et al. 2004; Nagueh
et al. 2004). In contrast, recent measurements in cardio-
myocytes isolated from catheter biopsies from patients
with less severe forms of heart failure (NYHA II-III)
revealed enhanced cardiomyocyte stiffness in all heart
failure patients, which was largely corrected with PKA
(Borbe´ly et al. 2005; van Heerebeek et al. 2006, 2008). In
these samples, a similar shift in titin isoform composition
was found as observed in end-stage heart failure. However,
analysis of titin phosphorylation indicated differential titin
isoform phosphorylation as possible cause for enhanced
cardiomyocyte stiffness and may involve reduced protein
kinase G-mediated phosphorylation (Kru¨ger et al. 2007;
Hamdani et al. 2007).
The functional consequences of impaired PKA-medi-
ated phosphorylation may be balanced by changes in other
kinases. In congestive heart failure models in rat (pressure
overload and MI), reductions in Fmax and in Ca2?-sensi-
tivity were associated with increased protein kinase C
(PKC) expression (Belin et al. 2007). Increased phos-
phorylation of cTnI was observed in failing rat
myocardium and deficits in myofilament function were
corrected by phosphatase treatment. It has been proposed
that the relative balance of phosphorylation of the 3 PKC-
sites on cTnI (Ser 43/45 and Thr 144) is important for the
regulation of its function (Solaro et al. 2008). Pseud-
ophosphorylation of Ser 43/45 significantly reduced
myofilament response to Ca2? (Burkart et al. 2003) and
phosphorylation of Thr 144 induced an increase in sensi-
tivity to Ca2? (Sumandea et al. 2003). Increased PKC
activity and isoform expression has been reported in human
heart failure (Bowling et al. 1999; Takeishi et al. 2000;
Braz et al. 2004). However, it remains to be investigated if
PKC targets the myofilament proteins in vivo (Huang and
Walker 2004). Recent mass spectrometry analysis revealed
a novel in vivo phosphorylation site in human cTnI (Ser 76/
Thr 77), which may be target of PKC (Zabrouskov et al.
2008). To establish if PKC-mediated protein phosphory-
lation impacts myofilament function in human cardiac
disease quantitative mass spectrometry should be per-
formed in cardiac samples, which are obtained under well-
defined conditions, preferably before and after in vivo
receptor stimulation.
Reduced maximal force generating capacity
The maximal force generating capacity of cardiomyocytes
from remodelled myocardium early after a myocardial
infarction was reduced and, unlike pCa50 and Fpas, was not
corrected by PKA. An important role has been assigned to
PKC-mediated phosphorylation of cTnT at Thr 206 (Su-
mandea et al. 2003), and cTnI at Ser 43/45 (Burkart et al.
2003) in reducing myofilament Fmax. However, up to date,
no changes in cTnT phosphorylation have been reported in
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any heart failure model (Fig. 6). Moreover, using an ele-
gant troponin exchange method in failing and non-failing
rat cardiomyocytes, Belin et al. (2006) showed that
replacement of failing troponin by non-failing troponin
restored myofilament Ca2?-sensitivity to values observed
in non-failing cardiomyocytes, but not Fmax. Hence,
alterations in troponin phosphorylation underlie changes in
myofilament Ca2?-sensitivity, but are not the cause of
reduced maximal force generating capacity.
In our previous study in MI mice (de Waard et al. 2007),
exercise prevented the reduction in Fmax, which was
associated with an increase in MLC2 phosphorylation,
although MLC2 phosphorylation was not significantly
reduced in MI (Fig. 6b, c). A transmural gradient in MLC2
phosphorylation has been described in rodent studies
(Davis et al. 2001; Rajashree et al. 2005; Cazorla et al.
2005). A reduction in MLC2 phosphorylation in myocar-
dium from MI mice may have been obscured by regional
differences, as a significant reduction in MLC2 phosphor-
ylation was observed in subendocardial tissue from MI pigs
(Fig. 6b, c). Accordingly, a recent study in rats with
ischaemic heart failure (Aı¨t Mou et al. 2008) revealed
impaired contractile function and reduced MLC2 phos-
phorylation only in subendocardial cardiomyocytes, which
were both restored by exercise training. It has been pro-
posed that the overall pattern of cardiac contraction
depends on a spatial gradient of MLC2 phosphorylation
(Davis et al. 2001), and loss of the MLC2 phosphorylation
gradient may impair cardiac performance (Davis et al.
2001; Cazorla et al. 2005). Hence, myofilament function
may be hampered by alterations in MLC2 phosphorylation.
Investigation of transmural biopsies taken under well-
controlled hemodynamic conditions allow careful analysis
of MLC2 phosphorylation at rest and during enhanced
cardiac load (i.e., upon receptor stimulation) and would
allow investigation of the importance of a transmural
MLC2 phosphorylation gradient for cardiac contraction in
a large animal model. As the opposite changes in MLC2
phosphorylation in animal models with ischemic heart
disease (reduction) and end-stage failing human ischemic
cardiomyopathy (increase) may relate to severity of cardiac
disease, changes during the progression of cardiac disease
should be addressed as well.
In conclusion, cardiomyocyte force measurements
revealed enhanced myofilament Ca2?-sensitivity and pas-
sive stiffness, which were both largely corrected with
exogenous PKA indicative for hypo-phosphorylation of b-
AR target proteins. When translated to in vivo cardiac
performance, an enhancement in myofilament Ca2?-sensi-
tivity and cardiomyocyte stiffness would both limit cardiac
relaxation. This is illustrated by the positive correlation
between high left ventricular end-diastolic pressures
(LVEDP) in heart failure patients and high cardiomyocyte
stiffness (Borbe´ly et al. 2005). As high LVEDP could not
be solely attributed to increased cardiac collagen, high LV
filling pressures may be in part explained by high intrinsic
stiffness of the cardiomyocytes. Though limiting relaxa-
tion, the enhanced myofilament Ca2?-sensitivity might
increase cardiomyocyte force development and increase
cardiac contractility.
Although the enhanced myofilament Ca2?-sensitivity in
failing myocardium would enhance cardiomyocyte con-
tractility, a reduction in Fmax would counteract this. This
is illustrated by the relationship between absolute force
development and pCa in Fig. 2b. In vivo, the impact of
altered myofilament function depends on cytosolic [Ca2?]
during the different phases of the cardiac cycle. As systolic
calcium levels are reduced in failing cardiomyocytes, it
may be speculated that myofilament dysfunction in
remodelled myocardium after MI further deteriorates car-
diac performance.
Future perspective
Our data illustrate the need for careful tissue handling
under well-defined conditions, preferably at the time of
hemodynamic measurements, and careful analysis of the
myofilament phosphoproteome. Research on the cellular
mechanisms underlying human heart failure is hampered
by the limited availability of biopsy material and, since
biopsies are routinely obtained at one time point, by the
lack of information on the dynamic aspects of the processes
involved. The dynamic changes in cellular signalling crit-
ically depend on the phosphorylation status of a number of
target proteins. Analysis of dynamic changes in intracel-
lular signalling pathways and the interaction between
kinases and phosphatases and their specific myofilament
target proteins within intact cells is essential to establish a
direct relation between changes in myofilament protein
phosphorylation and myofilament dysfunction in heart
failure.
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